The identification of small molecule inhibitors of antiapoptotic Bcl-2 family members has opened up new therapeutic opportunities, while the vast diversity of chemical structures and biological activities of natural products are yet to be systematically exploited. Here we report the identification of chelerythrine as an inhibitor of BclXL-Bak Bcl-2 homology 3 (BH3) domain binding through a high throughput screening of 107,423 extracts derived from natural products. Chelerythrine inhibited the BclXL-Bak BH3 peptide binding with IC50 of 1.5 μm and displaced Bax, a BH3-containing protein, from BclXL. Mammalian cells treated with chelerythrine underwent apoptosis with characteristic features that suggest involvement of the mitochondrial pathway. While staurosporine, H7, etoposide, and chelerythrine released cytochrome c from mitochondria in intact cells, only chelerythrine released cytochrome c from isolated mitochondria. Furthermore BclXL-overexpressing cells that were completely resistant to apoptotic stimuli used in this study remained sensitive to chelerythrine. Although chelerythrine is widely known as a protein kinase C inhibitor, the mechanism by which it mediates apoptosis remain controversial. Our data suggest that chelerythrine triggers apoptosis through a mechanism that involves direct targeting of Bcl-2 family proteins.
19 February 2004 in Clinical and Experimental Pharmacology and Physiology
SUMMARY: 1. Proteins of the Bcl‐2 family are central regulators of apoptosis and are thought to act primarily on the mitochondria.2. Members of the Bcl‐2 family possess either anti‐apoptotic or pro‐apoptotic function. They are characterized by the presence of conserved sequence motifs, known as Bcl‐2 homology (BH) domains. Anti‐apoptotic members share all four BH domains, designated as BH1‐4; the multidomain pro‐apoptotic members contain BH1‐3 domains, whereas another subgroup of pro‐apoptotic members only have a BH3 domain.3. The BH3‐only proteins act as sensors for distinct apoptosis pathways, whereas multidomain pro‐apoptotic Bax and Bak are executioners of death orders relayed by the BH3‐only proteins.4. Anti‐apoptotic Bcl‐2 family members appear to function, at least in part, by interacting with and antagonizing pro‐apoptotic family members. The BH1‐3 domains of BclXL form an elongated hydrophobic groove, which is the docking site for the BH3 domains of pro‐apoptotic binding partners.5. The deregulation of the various Bcl‐2 proteins has been implicated in many pathological conditions.6. Knowledge derived from the understanding of the function and regulation of the Bcl‐2 family of proteins has allowed us to contemplate new therapeutic strategies for diseases where apoptosis signalling mechanisms can potentially be manipulated.7. The anti‐apoptotic Bcl‐2 members have been targeted successfully using an antisense approach, BH3‐peptides and small molecular weight chemicals that are inhibitors of their anti‐apoptotic function.